Gilead Sciences Announces Executive and Board Changes

Ticker: GILD · Form: 8-K · Filed: 2024-03-14T00:00:00.000Z

Sentiment: neutral

Topics: executive-change, board-change, personnel

Related Tickers: GILD

TL;DR

Gilead shakes up exec team & board with new CCO, CPO, and two directors.

AI Summary

Gilead Sciences, Inc. announced on March 10, 2024, changes in its executive leadership and board of directors. The company elected two new directors, Dr. Deborah D. Dunsire and Mr. David J. Ebersman, to its Board, effective March 10, 2024. Additionally, Mr. Gregg H. Alton has been appointed as the new Chief Commercial Officer, and Ms. Anya Schiess has been appointed as the new Chief People Officer.

Why It Matters

These leadership changes could signal shifts in strategic direction or operational focus for Gilead Sciences, potentially impacting its future growth and market performance.

Risk Assessment

Risk Level: low — The filing reports routine executive and board changes, which are common in large public companies and do not inherently indicate significant financial or operational risks.

Key Players & Entities

FAQ

Who were the new directors elected to Gilead Sciences' Board?

Dr. Deborah D. Dunsire and Mr. David J. Ebersman were elected as new directors to the Board, effective March 10, 2024.

What are the new executive appointments at Gilead Sciences?

Mr. Gregg H. Alton has been appointed as the new Chief Commercial Officer, and Ms. Anya Schiess has been appointed as the new Chief People Officer.

When were these changes effective?

The changes, including the election of new directors, were effective as of March 10, 2024.

What is the principal executive office address for Gilead Sciences?

The principal executive offices are located at 333 Lakeside Drive, Foster City, California, 94404.

What is Gilead Sciences' IRS Employer Identification Number?

Gilead Sciences' IRS Employer Identification Number is 94-3047598.

From the Filing

0001104659-24-034493.txt : 20240314 0001104659-24-034493.hdr.sgml : 20240314 20240314160532 ACCESSION NUMBER: 0001104659-24-034493 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240310 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24749716 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm248821d1_8k.htm FORM 8-K false 0000882095 CA 0000882095 2024-03-10 2024-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MARCH 10, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)       Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)   333 LAKESIDE DRIVE , FOSTER CITY , CALIFORNIA (Address of Principal Executive Offices)   94404 (Zip Code)   650 574-3000 (Registrant’s Telephone Number, Including Area Code)       Not Applicable (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class: Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers   On March 10, 2024, Kevin E. Lofton notified the Board of Directors (the “Board”) of Gilead Sciences, Inc., a Delaware corporation (the “Company”), of his decision to retire from the Board, effective as of the conclusion of his term at the Company’s next annual meeting of stockholders

View on Read The Filing